CASE PRESENTATION

Type I Brugada syndrome with spontaneous intermittent normal electrocardiographic pattern
Mona Musteata¹², Radu Ciudin¹², Oana Andrei¹, Carmen Ginghina¹², Tiberiu Nanea²³

Abstract: In 1992, Brugada brothers published a study in which they described a novel autosomal dominant inherited disease, characterized by ST segment elevation in the right precordial leads, right bundle branch block and susceptibility to ventricular arrhythmias, all in the context of a structurally normal heart. We know today that there are at least 12 genes involved in the pathology of Brugada syndrome, and the best documented are SCN5A and CACN1Ac involved in the pathology of the cardiac sodium channel, confirming the hypothesis that Brugada syndrome is an electrical disease. The clinical manifestations of Brugada syndrome are syncope and/or cardiac arrest, typically occurring at rest or during sleep, especially in the third or the fourth decade of life. Male to female ratio is 8 to 1. The diagnosis of Brugada syndrome may be challenging because of the intermittent electrocardiographic pattern; one may need to perform provocative drug testing with Class IC anti-arrhythmic drugs such as ajmaline, flecainide or procainamide. In the ESC “Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death”, published in 2015 in European Heart Journal, the experts say that the implantation of cardiac defibrillator is the only effective treatment for reducing the risk of sudden cardiac death.

Keywords: spontaneous intermittent type I Brugada syndrome, cardiac defibrillator, primary prevention of sudden cardiac death, ventricular programmed stimulation

Resumat: În 1992 frații Brugada publicau un studiu în care descriau o afecțiune nouă, cu transmitere autozomal dominantă, caracterizată printr-o supradenivelare ascendentă de segment ST în derivațiile precordiale drepte (de la V1 la V3), bloc de ramură dreaptă și predispoziție pentru tahiaritmii ventriculare, totul în contextul unui cord structural normal. Astăzi, se consideră că cel puțin 12 gene sunt implicate în patologia sindromului Brugada, dintre care cele mai studiate sunt SCN5A și CACN1Ac, implicate în patologia canalului de sodiu, venind astfel în sprijinul ipotezei că sindromul Brugada este o boală electrică. Manifestările clinice constau în sincopă sau stop cardiac, cel mai frecvent instalate în repaus sau în somn, mai ales în decenii a 3-a și a 4-a de viață. Proporția manifestărilor clinice este de 8 bărbați la 1 femeie. Diagnosticul de sindrom Brugada poate fi, în multe cazuri, greu de stabilit, datorită patternului electrocardiografic intermittent; se știe că formele ascunse pot fi devoilate prin teste de provocare cu medicamente antiaritmice din clasa IC, de exemplu ajmalină, flecainidă sau procainamidă. În Ghidul Societății Europene de Cardiologie pentru Managementul pacienților cu aritmii ventriculare și de prevenție a morții subite cardiace publicat în 2015 în European Heart Journal, se specifică faptul că implantul de cardiodefibrilator este singurul tratament eficient pentru reducerea riscului de moarte subită cardiacă.

Cuvinte cheie: Sindică Brugada tip I spontan intermittent, defibrilator implantabil, profilaxia primară a morții subite cardiace, stimulare ventriculară programată

INTRODUCTION
Brugada syndrome, first described in 1992¹, is even nowadays, a disease in which the decision of a prophylactic therapy of sudden cardiac death (SCD) is difficult to make in borderline situations.

CASE REPORT
We present the case of a male patient, F.C., 36 years old, with positive cardiovascular risk factors (hypercholesterolemia, smoking), discovered by chance, at a routine examination at work, with an electrocardiographic pattern which was highly suggestive of Bruga-

¹ Emergency Institute for Cardiovascular Diseases “Prof. Dr. C. C. Iliescu” Bucharest
² University of Medicine and Pharmacy “Carol Davila”, Bucharest
³ University of Medicine and Pharmacy “Carol Davila”, Bucharest, Internal Medicine and Cardiology Department - “Theodor Burghhele” Clinical Hospital, Bucharest, Romania

Contact address:
Mona Musteata, MD
University of Medicine and Pharmacy “Carol Davila”
Emergency Institute for Cardiovascular Diseases “Prof. Dr. C. C. Iliescu”
Sos. Fundeni 258, sector 2, 022328, Bucharest, Romania
E-mail: monaa_dumitru@yahoo.com
da syndrome and who was admitted in our Clinic in November 2014 for further investigations. The patient recounts rare and brief episodes of palpitations. The patient has no personal history of SCD, syncope, documented ventricular rhythm disorders or known family history of SCD.

The physical examination on admission reveals a normal weight patient, with sinus tachycardia (100 beats per minute), a blood pressure of 120/60 mmHg, with no cardiac or vascular murmurs that could be heard and no signs of systemic or pulmonary stasis.

Biologically, the patient presented hypercholesterolemia; the thyroidian hormones were normal.

The resting electrocardiogram (ECG), on admission, reveals sinus tachycardia, 101bpm, an incomplete right bundle branch block with an important ST-segment elevation (descending type) from V1 to V2 and negative T wave in V1 and V2 (Figure 1).

We repeated the resting electrocardiograms throughout the period the patient was admitted in our clinic and on the third day of admission we found a completely different, yet spontaneously, electrocardiographic findings: sinus tachycardia, 100 bpm, and a perfectly normal looking QRS complex, with no T-wave changes (Figure 2) and then, a few days later, and spontaneously also, the patient had the same electrocardiographic pattern as on admission day.

The chest radiography is normal and so is the transthoracic echocardiography (Figure 3A and 3B).

The patient performed a cardiac stress test (by exercise on a treadmill) which proved to be negative for arrhythmias or conduction disturbances or ischemia and showed a normal capacity to tolerate effort. We emphasise the fact that the patient starts with a normal ECG (with no Brugada pattern) and throughout the test (for 9 minutes and 30 seconds) (Figure 4) and after it (Figure 5) the ECG remains normal.

The 24-hour Holter monitoring does not reveal any ventricular or supraventricular arrhythmias or conduction disturbances.
At that time, in November 2014, patients with Brugada syndrome who were asymptomatic and had no evidence of induced ventricular tachycardia/ventricular fibrillation had a Class III level of evidence C indication of internal cardiac defibrillator implantation, as it was recommended by the 2001 Task Force on Sudden Cardiac Death of the European Society of Cardiology.

We had also made recommendation of lifestyle changes to our patient, such as avoiding large meals and excessive alcohol intake and prompt treatment of any fever; we also recommended family screening.

At the 6th month control of the internal cardiac defibrillator, we interrogated the internal memory of the device and found no evidence of malignant ventricular arrhythmias.

DISCUSSIONS

In 1992, Brugada brothers published a study in which they described a novel autosomal dominant inherited disease, characterized by ST segment elevation in the right precordial leads, right bundle branch block and susceptibility to ventricular arrhythmias, all in the context of a structurally normal heart. The disease was named Brugada syndrome and its prevalence is higher in the Far East and there is a ratio of 8 male to 1 female in clinical manifestation.

The later on studies demonstrated a mutation on SCN5A gene, a mutation involved in the pathology of the cardiac sodium channel, confirming the hypothesis...
that Brugada syndrome is an electrical disease, clearly separated from those structural heart diseases that have a potential risk for ventricular arrhythmias. We know today that there are at least 12 genes involved in the pathology of the Brugada syndrome, and the best documented are SCN5A and CACN1Ac.

The clinical manifestations of the Brugada syndrome are syncope and/or cardiac arrest, typically occurring at rest or during sleep, especially in the third or the fourth decade of life.

The diagnosis of Brugada syndrome may be challenging because of the intermittent electrocardiographic pattern; one may need to perform provocative drug testing with Class IC anti-arrhythmic drugs such as ajmaline, flecainide or procainamide.

Our patient, in particular, presents a spontaneous intermittent electrocardiographic Brugada pattern, with a pathognomonic type I Brugada ECG on admission, and the next day, without any changes in his clinical or biological status, he presents a perfectly normal ECG.

There are numerous cases of intermittent electrocardiographic pattern Brugada syndrome described in the medical literature, but most of them came into medical attention because of their clinical manifestations: syncope, ventricular tachyarrhythmias, cardiac arrest or even mimicking an acute myocardial infarction.

We also want to emphasise on the importance of a well done ECG; a wrong position of the right precordial leads (VI-V2), with one or two intercostal spaces upwards, may create a false impression of a possible hidden Brugada syndrome.

In the clinical and the electrocardiographic context of our patient we considered it unnecessary to perform a challenging test with Class IC drugs, because the electrocardiographic changes at rest in our patient are pathognomonic for the type I Brugada syndrome.

From a prognostic point of view, the Brugada syndrome is responsible of 4-12% of all sudden cardiac deaths and at least 20% of sudden death with structurally normal heart.

No anti-arrhythmic drug was proven so far to be efficient in preventing malignant ventricular arrhythmias in Brugada syndrome; the best treatment in these cases remains the prophylaxis (primary or secondary) of SCD by implantation of cardiac defibrillator. In order to identify the patients at risk of developing such life-threatening arrhythmias, some specialists proposed a risk stratification scheme, using the history of syncope and the presence of a spontaneously electrocardiographic pattern as the clinic variables for quantification of risk.

We applied this scheme to our patient and it shows us that the patient belongs to the 41% of Brugada patients with intermediate risk, only by having a spontaneous Brugada pattern.

In this intricate context and because recent studies demonstrated that patients with spontaneous Brugada pattern have yet a high risk of developing malignant ventricular arrhythmias and there is no difference between the risk of the patients with intermittent electrocardiographic pattern and those with persistent electrocardiographic pattern, we decided to implant a cardiac defibrillator to our patient.

There is another discussion in this case, whether we should have performed a programmed ventricular stimulation (PVS) before the implant, in order to see if our patient is at risk of cardiac arrest. There is a disagreement between various electrophysiologists’ opinions at this moment; while Brugada and co-workers showed that PVS has a high sensitivity in predicting the risk of SCD, Priori, Gasparini, Eckardt and others failed to demonstrate this.

Performing a PVS is a Class IIb level of evidence C recommendation on the 2001 Task Force on Sudden Cardiac Death of the European Society of Cardiology.

This is why we didn’t consider it necessary to perform a PVS before the implantation of cardiac defibrillator in our patient.

In the ESC “Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death”, published in 2015 in European Heart Journal, the experts say that the implantation of cardiac defibrillator is the only effective treatment for reducing the risk of sudden cardiac death; quinidine was proposed as a treatment to prevent malignant ventricular arrhythmias, because it was observed that it reduces VF inducibility during PVS (Class IIb level of evidence C recommendation) if PVS was made under anti-arrhythmic treatment, but there is no evidence to support quinidine’s role in preventing SCD, so far.

Conflict of interests: none declared.

References